Navigation Links
InterMune to Release Second Quarter Financial Results on July 27
Date:7/20/2010

BRISBANE, Calif., July 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release second quarter 2010 financial results on Tuesday, July 27, 2010 at 4:00 p.m. Eastern time.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 85459924.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call.  The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 85459924.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone, for which InterMune has completed the Phase 3 CAPACITY program in patients with IPF.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 and ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
2. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
3. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
4. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
5. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
6. InterMune to Present at Deutsche Bank Biotech Confab
7. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
8. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
9. InterMune to Present at JMP Securities Conference
10. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose Inhalers, Dry Powder ... Respiratory Inhalers - our new study reveals trends, R&D progress, and ... you are involved in this sector you must read this brand ... streams to 2027, assessing data, trends, opportunities and business prospects there. ... Discover how to ...
(Date:3/29/2017)... 2017 Wound care devices and products are ... wound. The industry mainly consists of establishments engaged in ... of wounds caused by mechanical, chemical, thermal, and radiogenic ... as diabetes, skin related diseases, immunological diseases, and other ... was the largest region in the wound care devices ...
(Date:3/29/2017)... 2017  BioSpecifics Technologies Corp. (NASDAQ: BSTC), a ... collagenase based-therapies with a first in class collagenase-based ... ®  in the U.S. and Xiapex ®  in Europe, ... overview at the upcoming 16 th Annual ... at 8:00 a.m. ET in New ...
Breaking Medicine Technology:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... A ... suggests that following joint replacement surgery – the best place for a patient to ... when they are in familiar surroundings and have ample opportunity to rest and recover ...
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... , ... March 30, 2017 , ... An inventor and manicurist from Greet, S.C., wants ... profession I try to help customers maintain clean and healthy feet, so I know the ... of their feet at home, I designed the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables ...
(Date:3/30/2017)... ... 30, 2017 , ... AudioEducator, a leader in training conferences ... Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, JD., ... to prevent readmissions in light of the most recent programs at the Centers ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week ... free screening colonoscopies to eligible individuals in the local community. , Colon cancer ... regular screenings can detect colon cancer while it is small, confined and easier to ...
Breaking Medicine News(10 mins):